Interconnected B-cells and skin tissue in Systemic Sclerosis

Unlocking Scleroderma: New Insights into Skin Fibrosis & B Cell Biomarkers

Samir D’Costa monogram
Samir D’Costa in Health & Wellness October 2026 • 6 min read.

"Groundbreaking research identifies potential markers for predicting skin progression and disease activity in Systemic Sclerosis, offering hope for targeted therapies."


Systemic Sclerosis (SSc), also known as scleroderma, is a chronic autoimmune disease characterized by hardening and thickening of the skin (fibrosis) and internal organ damage. Managing SSc is challenging due to its variable progression and the lack of reliable markers to predict outcomes. Recent research sheds light on potential biomarkers that could revolutionize how we understand and treat this complex condition.

Two studies presented at the European League Against Rheumatism (EULAR) 2016 congress offer new perspectives on SSc. One study investigates the relationship between active skin disease and the progression of skin fibrosis, while the other explores the role of B cells in disease activity and organ involvement. Understanding these factors could lead to more targeted and effective therapies for SSc patients.

This article breaks down the key findings of these studies, translating complex scientific data into accessible information for patients, caregivers, and anyone interested in learning more about SSc. We'll explore the implications of these findings for predicting disease progression, monitoring disease activity, and developing new treatment strategies.

AI Search Multiple angles on this topic

Systemic Sclerosis: Scope and Impact

Systemic sclerosis (SSc) is a rare, heterogeneous autoimmune disease involving immune dysregulation and autoantibodies, microvascular injury, and progressive fibrosis of the skin and internal organs. Its clinical range extends from mild skin manifestations and Raynaud’s phenomenon to aggressive multisystem disease affecting organs such as the lungs, heart, and pulmonary arteries. One cited report estimated about 49,000 U.S. adults had diagnosed systemic sclerosis. Global prevalence and incidence estimates are also studied, including population-based data from southern Sweden, but the provided material does not give a comparable global figure.

Guideline-Based Care and Treatment Gaps

The European Alliance of Associations for Rheumatology (EULAR) updated its systemic sclerosis treatment recommendations to incorporate new evidence and therapies, using an international task force and a two-round nominal group technique. Current treatment has often focused on symptom control or specific complications, including scleroderma renal crisis, pulmonary arterial hypertension, and digital ulcers. A 2019 review describes limited efficacy among many current treatments and ongoing unmet need. The supplied sources establish that recommendations are updated as evidence evolves, while noting persistent limitations in treatment effectiveness.

Decoding Skin Fibrosis: Is Active Skin Disease a Predictor of Progression?

Interconnected B-cells and skin tissue in Systemic Sclerosis

One of the major challenges in managing diffuse cutaneous SSc (dcSSc) is predicting which patients will experience rapid skin fibrosis progression. To address this, researchers conducted a longitudinal analysis of the EUSTAR registry, focusing on patients with dcSSc, a baseline mRSS (modified Rodnan skin score) of 7 or greater and available mRSS data at 12±2 months.

The study defined skin progression as an increase in mRSS of >5 points AND ≥25% within one year. They then analyzed various parameters of disease activity at baseline to see if they correlated with skin progression. These parameters included patient-reported worsening of skin, a modified skin thickness progression rate, progression of mRSS in the prior 12 months, the Valentini activity index, and inflammatory markers.

  • Patient-Reported Worsening: Surprisingly, patient-reported worsening of skin within the past month before baseline was not significantly associated with progressive skin disease after one year (p=0.774).
  • Modified Skin Progression Rate: The modified skin progression rate at baseline also did not differ significantly between progressive and non-progressive patients (p=0.323).
  • Prior Progression: Patients with skin fibrosis progression in the previous year were not more likely to show progression in the following year (p=0.385).
  • Other Activity Parameters: The Valentini activity index (p=0.673) and inflammatory markers like Erythrocyte Sedimentation Rate (p=0.287) and C-reactive protein (p=0.358) were not associated with skin fibrosis progression.
AI Search Multiple angles on this topic

Emerging Insights into SSc Biology

Systemic sclerosis is described as a multisystem connective-tissue disease involving autoimmunity, inflammation, fibrosis, and vasculopathy. Research reported in 2026 suggests that cytotoxic T cells are dominant in lesional skin in early diffuse cutaneous SSc and contribute to vasculopathy and tissue fibrosis. A 2026 review highlights how single-cell technologies, spatial omics, and large-scale genomic analyses are providing new insights into interactions between innate and adaptive immunity. These findings broaden investigation of disease mechanisms, but the supplied material does not report a clinical treatment outcome from them.

Skin Fibrosis Remains Difficult to Treat

Systemic sclerosis is a rare, complex autoimmune connective-tissue disease, and research advances have improved understanding of its pathogenesis and clinical phenotypes. However, a 2021 review reports that effective treatments for cutaneous fibrosis remain elusive despite progress in treating internal-organ involvement, including pulmonary disease. The review states that no disease-modifying antirheumatic drugs had shown proven efficacy for SSc skin fibrosis and that no FDA-approved medications for this problem were available at the time it was written. In limited cutaneous SSc, skin involvement is described as confined to the face, hands, forearms, lower legs, and feet.

Terminology and Diagnostic Distinctions

“Scleroderma” and “systemic sclerosis” are related terms, but the supplied sources emphasize that terminology matters. One source describes systemic sclerosis as a rare systemic connective-tissue disease marked by skin and internal-organ thickening and fibrosis, while conditions with similar clinical manifestations are called scleroderma-like syndromes. Another source explicitly addresses differences between scleroderma and systemic sclerosis, including localized and systemic forms. The supplied material does not provide enough detail to compare the specific diagnostic criteria or clinical outcomes of these categories.

These findings suggest that recently active skin disease, as measured by these parameters, may not be a reliable predictor of further skin fibrosis progression in dcSSc patients. The researchers propose that patients with recent active skin disease might have already reached their peak skin score, making further progression less likely. This challenges the notion of using recently active skin disease as an enrichment criterion in clinical trials targeting skin fibrosis.

The Future of SSc Research: Targeting B Cells and Beyond

These studies highlight the complex nature of SSc and the need for more refined approaches to predicting disease progression and tailoring treatment strategies. The identification of CD19 and plasmablasts as potential biomarkers opens new avenues for research and could lead to the development of targeted therapies that modulate B cell activity.

AI Search Multiple angles on this topic

Persistent Challenge of Cutaneous Fibrosis

Systemic sclerosis can affect internal organs as well as the skin, and pulmonary disease is one area where treatment progress has been reported. Yet effective treatments for cutaneous fibrosis, a hallmark of the disease, remain elusive according to the cited review. This contrast underscores a continuing challenge: progress in managing some internal-organ involvement has not resolved the treatment gap for skin fibrosis.

Future research should focus on validating these findings in larger, more diverse cohorts of SSc patients. Additionally, studies are needed to investigate the mechanisms by which B cells contribute to disease activity and organ involvement in SSc. This may lead to the identification of novel therapeutic targets for this challenging condition.

While these findings offer hope for improved management of SSc, it's important to remember that SSc is a highly variable disease. Patients should work closely with their healthcare providers to develop individualized treatment plans that address their specific needs and disease manifestations. Continued research and collaboration are essential to unlocking the mysteries of SSc and improving the lives of those affected by this condition.

  • 16Among 16 untreated patients, 9 had CD20+ cells in skin at baseline; 7 of those 9 experienced a worsening skin score, while none of the patients without these cells did (Fisher’s test, p = 0.03).[1]

What B-cell signals may mean for skin fibrosis

B cells may contribute to SSc through several routes, including autoantibody production and the release of signals that can promote inflammation or fibrosis. This offers a possible biological context for why B-cell measures are being examined alongside skin changes, but does not make any single marker a reliable predictor.[2] [3]

In cell coculture, B cells and dermal fibroblasts from people with SSc induced collagen secretion and other profibrotic responses; the reported effect was enhanced by BAFF. These laboratory observations support a possible role in fibrosis, but do not establish that changing BAFF will improve skin disease in patients.[4]

How related SSc findings compare

In a validation cohort of limited cutaneous SSc patients without extensive ILD, PAH was associated with lower serum IgG and higher β2-microglobulin, sBCMA, sCD23 and sCD27; this is a different clinical comparison from skin-score progression.[5]

A candidate serum marker, COL4A1, was numerically higher in early dcSSc patients not receiving standard-of-care treatment than in those receiving it, but the reported comparison was not statistically significant (P = 0.30).[6]

A validation effort for a skin-fibrosis assessment device noted that its small sample size was a limitation given the varied clinical presentation of SSc.[7]

What further evidence would need to show

  • Would a larger and more clinically varied sample confirm whether a skin-fibrosis assessment method performs consistently across SSc presentations?[7]

Terms used in B-cell research

Profibrotic cytokines
Cytokines that promote fibrotic processes.[3]
PAH
Pulmonary arterial hypertension.[5]

Sources

  1. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression (pmc.ncbi.nlm.nih.gov)
  2. Role of B-Cell in the Pathogenesis of Systemic Sclerosis (pmc.ncbi.nlm.nih.gov)
  3. Dysregulated B cell function and disease pathogenesis in systemic sclerosis (pmc.ncbi.nlm.nih.gov)
  4. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis (pmc.ncbi.nlm.nih.gov)
  5. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension (pmc.ncbi.nlm.nih.gov)
  6. Testing a candidate composite serum protein marker of skin severity in systemic sclerosis (pmc.ncbi.nlm.nih.gov)
  7. Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Systemic Sclerosis (SSc), and what are its key characteristics?

Systemic Sclerosis (SSc), often called scleroderma, is a chronic autoimmune condition. It's characterized by the hardening and thickening of the skin (fibrosis) and can also damage internal organs. The condition's progression varies, and there's a lack of consistent markers to predict how it will unfold. Recent research aims to identify biomarkers that could help us better understand and treat SSc, improving the lives of those affected by this challenging disease.

2

How was the study group defined in this research regarding skin progression?

The study mentioned in the article looked at a group of patients with diffuse cutaneous Systemic Sclerosis (dcSSc) who had an initial modified Rodnan skin score (mRSS) of 7 or higher and mRSS data available at 12±2 months. Skin progression was defined as an increase in the mRSS of more than 5 points and a rise of at least 25% within one year. The researchers examined various disease activity parameters at the start to see if they related to skin progression, which included patient-reported worsening of skin, a modified skin thickness progression rate, progression of mRSS in the prior 12 months, the Valentini activity index, and inflammatory markers.

3

What were the main findings regarding active skin disease and its relation to skin fibrosis progression?

The research indicates that recently active skin disease, based on parameters like patient-reported worsening and skin thickness changes, may not reliably predict the progression of skin fibrosis in patients with dcSSc. The study found no significant associations between these factors and future skin fibrosis. This suggests that patients with recent active skin disease might have already reached their peak skin involvement, making further progression less likely. This challenges the common assumption of using recently active skin disease in clinical trials that target skin fibrosis.

4

Were inflammatory markers associated with skin fibrosis progression?

The Valentini activity index, Erythrocyte Sedimentation Rate (ESR), and C-reactive protein (CRP) were all investigated in the research. However, the research showed that they were not associated with skin fibrosis progression. This suggests that these measures, which are often used to assess inflammation and disease activity, may not be accurate in predicting the worsening of skin fibrosis in dcSSc patients. Other factors need to be considered to better predict disease progression and help in developing more effective treatments.

5

Why are B cells important in Systemic Sclerosis research?

B cells and their related biomarkers, such as CD19 and plasmablasts, are seen as significant in disease activity and organ involvement in Systemic Sclerosis. Identifying and targeting these specific B cell biomarkers opens new avenues for treatment research. These new approaches could lead to therapies that adjust B cell activity, offering more targeted and effective ways to treat Systemic Sclerosis. These findings show that the complexity of Systemic SSc requires detailed approaches and new strategies.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.